Skip to main content
menu sluit menu
Home Home
Login
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
User tools menu
User tools menu
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
Follow IVIS
  • Twitter
  • Facebook
Support IVIS

Breadcrumb

  1. Home
  2. Library
  3. Encyclopedia of Canine Clinical Nutrition
  4. Treatment of Hyperlipidemia
Encyclopedia of Canine Clinical Nutrition
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Comments
Print this article
Share:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter

Treatment of Hyperlipidemia

Author(s):
Schenck P.A.
In: Encyclopedia of Canine Clinical Nutrition by Pibot P. et al.
Updated:
APR 21, 2008
Languages:
  • DE
  • EN
  • ES
  • FR
  • IT
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Print this article
SHARE:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter
    Read

    6. Treatment of Hyperlipidemia

    Because of the potential risks associated with persistent hyperlipidemia, hyperlipidemia should be treated aggressively. The underlying disorder in secondary hyperlipidemias should be treated, but there is no specific therapeutic regimen for dogs with idiopathic hyperlipoproteinemias. Unfortunately since little is known regarding the mechanisms of primary hyperlipidemia, and multiple syndromes most likely exist, no single treatment regimen has been effective in all cases.

    Caution must be exercised when considering dietary fat content on only a percentage basis. For example, a diet containing 10% fat with an ME of 4000 kcal/kg provides only 25 g fat/1000 kcal, whereas a diet containing 8% fat with an ME of 2700 kcal/kg provides 30 gfat/1000 kcal.

    Nutritional Treatment of Hyperlipidemia

    A Fat-restricted Diet

    Initial treatment of primary hyperlipidemia involves a switch to a low-fat diet (<25 g/1000 kcal) with moderate protein content (generally greater than 18%, or 60 g protein/1000 kcal). Diets low in protein may cause an increase in serum cholesterol concentration (Polzin et al., 1983; Hansen et al., 1992) and are therefore not recommended unless the presence of other conditions warrant their use. Numerous nutritionally complete, low-fat canine diets are commercially available, but one must be careful to choose a diet that is low in fat based on a metabolizable energy (ME), and not strictly on the percent fat present in the diet. Most diets with a fat content less than 8% will provide less than 25g fat/1000 kcal. However, some diets appear low in fat on a percentage basis (<8%), but actually provide substantially more than 25 g fat/1000 kcal when the amount of fiber in the diet and metabolizable energy are taken into account, and thus are not low-fat diets.

    After feeding a low-fat diet for 6 to 8 weeks, the presence of hyperlipidemia should be re-evaluated. Low-fat diets alone may not cause resolution of hyperlipidemia, especially when there is a high concentration of endogenous triglyceride (VLDL-TG) (Bauer, 1995).

    Omega-3 Fatty Acid Supplementation

    If hyperlipidemia is still present after 6 to 8 weeks, then fish oil at a dose of 220 mg/ kg of body weight (BW) once daily should be added to the treatment regimen. Fish oil capsules may be obtained over-the-counter, but labels should be read carefully to ensure that the dog receives 220 mg/kg BW of a combination of alpha-linolenic acid, and the long chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Some products claim to be "omega-3 supplements", but contain a high percentage of other non-omega-3 fatty acids.

    In the author's experience the only side effect noted with this level of fish oil supplementation is that the dog may have a noticeable "fishy" odor which may be objectionable to some owners. If hyperlipidemia resolves with this level of fish oil supplementation and the owner complains about the fishy odor, a half-dose (110 mg fish oil/kg BW/day) can be evaluated. A few dogs can be managed at this dose; however, most will require a minimum of 170 mg fish oil/kg BW/day to maintain the absence of hyperlipidemia. In one particular case in the author's experience, a 6 year-old Shetland Sheepdog with idiopathic hyperlipoproteinemia and multiple lipomas showed complete resolution of serum hyperlipidemia, hypertriglyceridemia, and hypercholesterolemia after 4 weeks on a low-fat diet and 220 mg fish oil/kg BW/day. In addition, most of the lipomas resolved. Due to the dog's fishy odor, the dosage of fish oil was dropped to 110 mg/kg BW/day, with a return of hyperlipidemia. A dosage of 170 mg fish oil/kg BW/day in combination with a low-fat diet has maintained the absence of hyperlipidemia for over one year.

    The use of fish oil and EPA & DHA in the treatment of hyperlipidemia and atherosclerosis has been extensively studied in a number of species.

    • EPA supplementation resulted in a 31% decrease in serum triglyceride in human patients (Okumura et al., 2002).
    • Rats fed diets containing EPA and DHA exhibited a decrease in serum cholesterol and triglyceride and the development of atherosclerosis was prevented (Adan et al., 1999).
    • Fish oil supplementation decreased serum triglyceride, total cholesterol, VLDL-triglyceride and VLDL-cholesterol in chicks (Castillo et al., 2000).
    • In dogs with renal insufficiency, fish oil supplementation resulted in a decrease in serum cholesterol concentration (Brown et al., 2000).
    • Watanabe heritable hyperlipidemia (WHHL) rabbits exhibited a decrease in serum triglyceride and cholesterol with a decrease in VLDL-triglyceride (Mortensen et al., 1998).

    Fish oil and omega-3 fatty acids
    Fish oil and omega-3 fatty acids. Synthesis of triglyceride and VLDL in the liver is decreased by omega-3 fatty acids (Harris et al., 1990; Connor et al., 1993), and the effectiveness of fish oils in dogs with hyperlipidemia suggests that the hypertriglyceridemia may be partly due to overproduction of VLDL (Bauer, 1995).

    Fish oils may exert a beneficial effect on hyperlipidemia by stimulating lipoprotein lipase activity (Levy et al., 1993), decreasing the intestinal absorption of glucose and lipid (Thomson et al., 1993), increasing cholesterol secretion into bile (Smit et al., 1991) and by decreasing cholesterol absorption (Thompson et al., 1989). Fish oils also decrease serum concentration of free fatty acids (Singer et al., 1990) which may be important in the prevention of pancreatitis and diabetes mellitus. Development of atherosclerosis may be prevented by fish oil due to an inhibition of mitogen-induced smooth muscle cell proliferation (Pakala et al., 2000).

    Unfortunately there are no long-term studies to verify the safety and efficacy of any lipid-lowering agent in dogs, and any therapy should be used with caution. One concern with fish oil therapy is that fish oil increases the concentration of lipoperoxides in LDL (Puiggros et al., 2002). The addition of vitamin E to the fish oil therapy regimen may enhance beneficial effects by increasing glutathione reductase activity and decreasing peroxide levels (Hsu et al., 2001).

    In severe cases of lipoprotein lipase deficiency in human patients, fish oil and other dietary therapies result in some improvement, but serum lipids may remain elevated (Richter et al., 1992).

    Interest of Medium Chain Triglycerides

    In human patients, in addition to fish oil therapy, medium chain triglycerides (MCT) in combination with low-fat diets cause a decrease in hypertriglyceridemia (Rouis et al., 1997; Chou et al., 2002; Nagasaka et al., 2003). MCT administration results in increased lipoprotein lipase activity (Shirai et al., 1992) and may prevent hyperlipidemia associated pancreatitis (Mizushima et al., 1998). MCT administration does not lower, and may even elevate serum cholesterol concentration (Asakura et al., 2000). Therefore, MCT therapy should only be used in cases where there is elevation of serum triglyceride concentration without a high elevation in serum cholesterol. Unfortunately, MCT oil is not very palatable, limiting its use.

    Fermentable Fiber Intake

    The presence of a blend of fructooligosaccharides and beet pulp in the diet may also be desirable, since this blend can decrease serum triglyceride and cholesterol concentrations in the dog (Diez et al., 1997).

    Antioxidant Treatment

    Since the pathogenesis for idiopathic hyperlipoproteinemia has been at least partly determined (Schenck, 2002), treatments that have been effective in human patients with lipoprotein lipase deficiency may be worthy of investigation.

    Several humans with familial lipoprotein lipase deficiency treated with a combination of oral antioxidant therapy (OAT) showed prevention of recurrent pancreatitis even though there was no effect on circulating lipids (Heaney et al., 1999). Antioxidant therapy consisted of a combination of α-tocopherol, β-carotene, vitamin C, selenium, and methionine.

    Medical Treatment of Hyperlipidemia

    Other treatment regimens have been attempted with variable results.

    Gemfibrozil has been used to stimulate lipoprotein lipase activity and decrease VLDL secretion (Santamarina-Fojo et al., 1994).

    Niacin therapy has also been used in a few dogs; however, adverse effects have been noted in both dogs (Bauer, 1995), and humans (Kashyap et al., 2002).

    Dextrothyroxine administration significantly decreased serum lipids in dogs with induced hyperlipidemia and atherosclerosis (Nandan et al., 1975), though these effects may have been due to contamination of dextrothyroxine with L-thyroxine (Young et al., 1984). Dextrothyroxine administration in humans results in an approximately 18% decrease in serum total cholesterol (Brun et al., 1980), but is not vastly utilized as a treatment for hyperlipidemia due to a concurrent lowering of HDL cholesterol (Bantle et al., 1984). A major mechanism of cholesterol-lowering by thyroxine in humans is an increase in cholesteryl ester transfer protein (Berti et al., 2001); however, since dogs have little cholesteryl ester transfer protein, thyroxine may not be as effective. Thyroxine does have other lipid-lowering mechanisms, including an increase in hepatic lipase activity and increased conversion of IDL to LDL (Asami et al., 1999), and is effective in lowering lipid concentrations in hypothyroid dogs (Rogers et al., 1975b; Cortese et al., 1997). Since thyroxine is fairly well tolerated in the dog, an investigation of lipid-lowering properties in euthyroid dogs with primary hyperlipoproteinemia may be warranted.

    Gene therapy has been effective in mice (Zsigmond et al., 1997) and may become a clinical reality in the future for patients with severe dyslipidemias (Rader et al., 1999).

    Table 5. Lipoprotein changes in canine hyperlipidemias.a. Lipoprotein lipase activity.
    b. Presumptive decrease based on literature report and human findings.
    c. Presumptive decrease based on human findings.
    N : normal value
    - : no specific data

    Conclusion

    Many conditions may cause hyperlipidemia in the dog. Postprandial hyperlipidemia should always be verified, and secondary causes of hyperlipidemia must be ruled out before a diagnosis of primary hyperlipidemia can be made. Hyperlipidemias are characterized by a number of different changes in lipoprotein concentrations, depending on cause (Table 5). Treatment of the underlying cause of hyperlipidemia is usually effective at resolving the secondary hyperlipidemia. Primary hyperlipidemias should be aggressively treated because of the potential complications of persistent hyperlipidemia.

    Back to Table of Contents
    Add to My Library
    Close
    Would you like to add this to your library?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    Print this article
    References

    1. Adan Y, Shibata K, Sato M et al. Effects of docosahexaenoic and eicosapentaenoic acid on lipid metabolism, eicosanoid production, platelet aggregation and atherosclerosis in hypercholesterolemic rats. Biosci Biotechnol Biochem 1999; 63(1):111-9.

    ...
    Show all
    Comments (0)

    Ask the author

    0 comments
    Submit
    Close
    Would to like to further discuss this item?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    About

    How to reference this publication (Harvard system)?

    Schenck, P. A. (2008) “Treatment of Hyperlipidemia”, Encyclopedia of Canine Clinical Nutrition. Available at: https://www.ivis.org/library/encyclopedia-of-canine-clinical-nutrition/treatment-of-hyperlipidemia (Accessed: 09 February 2023).

    Affiliation of the authors at the time of publication

    College of Veterinary Medicine, Michigan State University, MI, USA.

    Author(s)

    • Schenck P.A.

      DVM MA PhD
      Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University
      Read more about this author

    Copyright Statement

    © All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.
    Related Content

    Readers also viewed these publications

    • Journal Issue

      Veterinary Evidence - Vol 8 N°1, Jan-Mar 2023

      In: Veterinary Evidence
      FEB 05, 2023
    • Journal Issue

      Veterinary Evidence - Vol 7 N°4, Oct-Dec 2022

      In: Veterinary Evidence
      JAN 16, 2023
    • Proceeding

      SFT - Theriogenology Annual Conference - Bellevue, 2022

      By: Society for Theriogenology
      JAN 10, 2023
    • Journal Issue

      Urgencias y cuidados intensivos - Argos N°244, Diciembre 2022

      In: Argos
      DEC 31, 2022
    • Journal Issue

      Israel Journal of Veterinary Medicine - Vol. 77(4), Dec. 2022

      In: Israel Journal of Veterinary Medicine
      DEC 31, 2022
    • Proceeding

      ISCFR-EVSSAR Symposium - Italy 2022

      By: International Symposium on Canine and Feline Reproduction
      DEC 02, 2022
    • Journal Issue

      Patología endocrina - Argos N°243, Noviembre 2022

      In: Argos
      NOV 27, 2022
    • Proceeding

      ACVIM & ECEIM - Consensus Statements

      By: American College of Veterinary Internal Medicine
      NOV 11, 2022
    • Journal Issue

      Traumatología y neurología - Argos Nº242, Octubre 2022

      In: Argos
      NOV 10, 2022
    • Chapter

      Tibia and Tarsus

      In: Current Techniques in Small Animal Surgery (5th Edition)
      NOV 07, 2022
    • Chapter

      Femur and Stifle Joint

      In: Current Techniques in Small Animal Surgery (5th Edition)
      OCT 28, 2022
    • Journal Issue

      Medicina felina - Argos Nº241, Septiembre 2022

      In: Argos
      OCT 24, 2022
    • Chapter

      Sacroiliac Joint, Pelvis, and Hip Joint

      In: Current Techniques in Small Animal Surgery (5th Edition)
      OCT 17, 2022
    • Journal Issue

      Veterinary Evidence - Vol 7 N°2, Apr-Jun 2022

      In: Veterinary Evidence
      OCT 07, 2022
    • Journal Issue

      Veterinary Evidence - Vol 7 N°3, Jul-Sep 2022

      In: Veterinary Evidence
      OCT 04, 2022
    • Chapter

      Amputation of the Forelimb

      In: Current Techniques in Small Animal Surgery (5th Edition)
      OCT 02, 2022
    • Journal Issue

      Israel Journal of Veterinary Medicine - Vol. 77(3), Sep. 2022

      In: Israel Journal of Veterinary Medicine
      SEP 30, 2022
    • Chapter

      Carpus, Metacarpus, and Phalanges

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 26, 2022
    • Chapter

      Radius and Ulna

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 16, 2022
    • Chapter

      Humerus and Elbow Joint

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 10, 2022
    • Chapter

      Scapula and Shoulder Joint

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 05, 2022
    • Chapter

      Bone Grafts and Implants

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 03, 2022
    • Chapter

      External Skeletal Fixation

      In: Current Techniques in Small Animal Surgery (5th Edition)
      AUG 28, 2022
    • Chapter

      Plate-Rod Fixation

      In: Current Techniques in Small Animal Surgery (5th Edition)
      AUG 18, 2022
    • Chapter

      Fixation with Screws and Bone Plates

      In: Current Techniques in Small Animal Surgery (5th Edition)
      AUG 15, 2022
    • Load more
    Back To Top
    Become a member of IVIS and get access to all our resources
    Create an account
    Sign in
    Leading the way in providing veterinary information
    About IVIS
    • Mission
    • What we do
    • Who we are
    Need help?
    • Contact
    Follow IVIS
    • Twitter
    • Facebook
    International Veterinary Information Service (IVIS) is a not-for-profit organization established to provide information to veterinarians, veterinary students, technicians and animal health professionals worldwide using Internet technology.
    Support IVIS
    © 2023 International Veterinary Information Service
    • Disclaimer
    • Privacy Policy